Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
0.591
-0.031 (-5.03%)
Nov 21, 2024, 10:06 AM EST - Market open
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc.
| Country | United States |
| Founded | 1994 |
| IPO Date | Jan 5, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
| Phone | 212 994 8200 |
| Website | protagenic.com |
Stock Details
| Ticker Symbol | PTIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N103 |
| ISIN Number | US74365N2027 |
| Employer ID | 06-1390025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garo H. Armen Ph.D. | Co-Founder and Executive Chairman of the Board |
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer and Secretary |
| Dr. Andrew Slee Ph.D. | Chief Operating Officer |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 26, 2024 | 8-K | Current Report |
| Jun 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 24, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |